Overview

Tesofensine is a small-molecule triple monoamine reuptake inhibitor. In vitro it potently blocked dopamine, norepinephrine and serotonin reuptake (Bello 2009). It is not a peptide. This article summarises the mechanism work in rodents and the published clinical data, and states where the evidence stops. Stackpure supplies tesofensine for laboratory research only.

Mechanism in rodent models

In diet-induced obese rats, tesofensine at 2.0 mg/kg subcutaneously for 16 days gave lower body weights than vehicle, with a dose-dependent fall in food intake (ED50 1.3 mg/kg). The reduced intake was almost completely reversed by an alpha-1 adrenoceptor antagonist and partially by a dopamine D1 antagonist, but not by alpha-2 or D2 antagonists (Axel 2010). A later mouse and rat study found tesofensine caused greater weight loss in obese than lean rats and inhibited a subset of lateral hypothalamus GABAergic neurons that promote feeding (Perez 2024).

FindingModelSource
Dose-dependent hypophagia, ED50 1.3 mg/kg; reversed by alpha-1 and partly D1 antagonistsDiet-induced obese ratsAxel 2010
Greater weight loss in obese than lean rats; inhibited lateral hypothalamus GABAergic neuronsRats and micePerez 2024
Weight change after 14 weeks: +0.5% placebo vs -2.8% at 1.0 mgMeta-analysis of 4 trials in Parkinson or Alzheimer disease (n=740 drug, 228 placebo)Astrup 2008
Heart rate +6.8 bpm at 1.0 mg vs placebo; no blood pressure effectSame meta-analysisAstrup 2008
Phase II: dose-related falls in weight, fat and waist; higher dose raised blood pressureReview of obesity trialsBello 2009

Published clinical data

Tesofensine was first developed for neurodegenerative disease, where it was ineffective, but unintended weight loss was noticed. In four randomized trials in Parkinson or Alzheimer disease, 14-week weight change was dose-dependent, about 4% placebo-subtracted at the top dose, with heart rate rising dose-dependently (Astrup 2008). Phase II obesity trials showed dose-related reductions in body weight, body fat and waist circumference. Heart rate rose dose-dependently, and blood pressure rose significantly at the highest dose tested (Bello 2009).

What the sources do not show

  • The sources checked are rodent studies, a trial meta-analysis and a review. They do not describe tesofensine as a research peptide or give handling data for the capsule format.
  • Long-term safety and phase III outcomes are not reported in the sources checked.
  • Blood pressure findings differ between sources (no effect in Astrup 2008, a rise at the highest dose in Bello 2009).

Related research products and tools

Frequently Asked Questions

What is tesofensine?

A triple monoamine reuptake inhibitor that blocks dopamine, norepinephrine and serotonin reuptake (Bello 2009).

How does it reduce food intake in rats?

The effect depended on alpha-1 adrenoceptor and partly dopamine D1 pathways (Axel 2010).

Is tesofensine a peptide?

No. It is a small molecule.

Key References

  • Bello NT, Zahner MR. Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity. Curr Opin Investig Drugs. 2009. PubMed 19777399
  • Astrup A, et al. Weight loss produced by tesofensine in patients with Parkinson or Alzheimer disease. Obesity. 2008. PubMed 18356831
  • Axel AM, et al. Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat. Neuropsychopharmacology. 2010. PubMed 20200509
  • Perez CI, et al. Tesofensine, a novel antiobesity drug, silences GABAergic hypothalamic neurons. PLoS One. 2024. PubMed 38656972

For research use only. Not for human consumption.